Advertisement
"We are extremely pleased to welcome Charley to Abingdon as head of ourRegulatory Science Department," said Aidan Nuttall, Ph.D., Abingdon'sPresident and COO. "Charley brings a wealth of experience to the company. Heis a proven leader and has an extremely successful track record in regulatoryaffairs. He will certainly be a powerful asset to our clients. In recognitionof the ever-changing complexity of global regulatory requirements, our clientsneed for regulatory intelligence and analysis we have re-named our RegulatoryAffairs department to Regulatory Science to more accurately reflect theoperations within that department. Charley will be leading that developmentand we are confident our clients will appreciate the benefits of having him onAbingdon's team," continued Dr. Nuttall. "I am very pleased to be joining theworld class team at Abingdon and certainly look forward to being able tocontribute to Abingdon and the unique regulatory science challenges of ourclient companies," said Mr. Davis.
Advertisement
Mr. Davis joins Abingdon from Santarus Pharmaceuticals where he was SeniorDirector, Regulatory Affairs. Mr. Davis, with over twenty years of regulatoryexperience, has brought both drug and biologic products to commercial launchin the fields of cardiac imaging, coronary angioplasty, oncology,gastroenterology, parenteral nutrition, ophthalmology and contraception.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and DeviceDevelopment Management Organization (DDMO) providing drug and device companiessuperior clinical and regulatory services based on an integrated strategicdevelopment model. Abingdon's senior executives provide personalized oversightand leadership of projects to ensure the best possible customer experience.
SOURCE Abingdon Life Sciences, Inc.
